common folates and from methotrexate, the procedure is suitable for monitoring it in plasma of patients receiving high-dose therapy with methotrexate.
AddItIonal Keyphrases: monitoring therapy . cancer folate Methotrexate in high doses, with 5-ITHF "rescue," has been used clinically for several years in the treatment for various cancers (1) (2) (3) (4) (5) . 3 Recently, a "rescue" effect on the side effects of HDMT in tumor treatment has been also demonstrated with 5-MTHF, the predominant circulating form of folate
in experimental animals (9) (10) (11) and man (12, 13). As compared with 5-fTHF, 5-MTHF was found to be more effective, and less toxic, in Walker 256 carcinosarcoma-bearing rats and in CDF/1 mice with leukemia L 1210 (11) . The life span in CDF/1 mice with MTX-treated lymphatic leukemia was also more prolonged after 5-MTHF than after 5-tTHF (11) . In man, the protection against MTX toxic effects afforded by 5-MTHF was demonstrated in various malignant neoplasms (12, 13) , and it exceeded that obtained by 5-fTHF (12) .
An adequate concentration of 5-MTHF in the blood is required in the first phase of "rescue,"
to inhibit entry of the antifolic agent into the cell. For monitoring 5-MTHF in plasma in the presence of MTX or other folates, we describe a simple HPLC method, which allows evaluation even of the basal concentrations normally present in plasma. This procedure may also be useful when 5-ITHF "rescue" is used,
because 5-ITHF is converted to 5-MTHF in vivo (7, 9). 
Materials and Methods

Reagents
Sample preparation.
Heparinized blood was stored at 0-4 #{176}C before centrifugation, also at 4#{176}C. Ascorbic acid (5 mg/mL) was added to the plasma, and the specimens were frozen and kept at -20 #{176}C until analysis. Then, 4 zL of 1 molfL Na2CO3 was added to 0.3 mL of plasma and the mixture was stirred and heated in boiling water for 5 mm (15) . After cooling on ice and breaking the protein clot with a stainless-steel needle, we centrifuged the specimens in a Beckman Microfuge for 5 mm. Aliquots (10-50 sL) of the supernatant fluid were injected into the chromatograph.
Under these conditions, mean analytical recovery of added 5-MTHF from plasma was 93% (SEM, 3%, n = 10), ensuring that there was no decomposition of the compound during boiling the sample in the presence of ascorbate.
Chromatographic separation.
We used a Perkin-Elmer liquid chromatograph equipped with two pumps, series 3, a variable-wavelength ultraviolet detector LC 75, and a spectrophotofluorometer 650-10 LC. The detector was set at 295 and 350 nm for excitation and emission, respectively. The separation was performed at room temperature on a Lichrosorb RP-18 5sm, 0.4 X 25 cm column (Merck) by eluting at 1 mL/min with a mobile phase, used also for the column conditioning, that we prepared as follows: a 25 mmol/L solution of tetrabutylammonium phosphate in methanol was filtered through a 0.2-sm membrane (Sartorius GmbH, GOttingen, F.R.G.). To 200 mL of the filtrate 0.1 mol of H3PO4 and 680 mL of freshly glass-distilled water were added. The pH was adjusted to 4.5 with 1 mollL NaOH and the solution was diluted to a final volume of 1 L, filtered through a 0.2-tim membrane, and degassed under reduced pressure. Such a solution gives noticeably less baseline noise. Figure 1 illustrates the resolution of the tested folates from one another and from MTX under the chosen conditions. The fluorometric analysis ( Figure 1) shows that MTX, 5-fTHF, and FA are not revealed at the wavelengths used when 5-MTHF gives a very intense signal. THF gives rise to three agreement with those resulting from the regression lines calculated for calibration curves on the same plasma samples: 6.7 ± 2.7 and 8.2 ± 2.5 ( Figure 2 ). Basal 5-MTHF concentrations, measured in nine ostensibly healthy subjects, were 5.12 ± 0.44 g/L, in accordance with those determined by authors (7) who used microbiological assay (4.8 ± 0.28). By the present method, 5-MTHF plasma kinetics were determined after intravenous administration of the drug to four dogs. Figure 3 shows the concentrations in plasma and the mean plasma decay curve. Results obtained for 5-MTHF for some persons being treated with HDMT are reported in Table 1 . 
Results
Discussion
